Skip to main content
Figure 1 | BMC Endocrine Disorders

Figure 1

From: Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

Figure 1

Plasma (A) and femur (B) levels of leptin (ng/ml), plasma (C) and femur (D) levels of adiponectin (ng/ml), plasma levels of osteocalcin (ng/ml) (E), and plasma levels of osteoprotegerin (OPG) (pg/ml) (F) in control (CTR) rats (n = 12), fenofibrate (FENO) (n = 11) and pioglitazone (PIO)-fed (n = 8) rats after 4 months of daily treatment. Data is presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.0001 significantly different compared to control, # P < 0.05, ### P < 0.0001 significantly different compared to the fenofibrate group.

Back to article page